Display options
Cite
Cangiano B, Cacciatore C, Persani L, et al. Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis. Endocrinol Diabetes Metab Case Rep. 2017;2017doi: 10.1530/EDM-17-0055.
Cangiano, B., Cacciatore, C., Persani, L., & Bonomi, M. (2017). Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis. Endocrinology, diabetes & metabolism case reports, 2017. https://doi.org/10.1530/EDM-17-0055
Cangiano, B, et al. "Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis." Endocrinology, diabetes & metabolism case reports vol. 2017 (2017). doi: https://doi.org/10.1530/EDM-17-0055
Cangiano B, Cacciatore C, Persani L, Bonomi M. Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis. Endocrinol Diabetes Metab Case Rep. 2017 Jul 07;2017. doi: 10.1530/EDM-17-0055. eCollection 2017. PMID: 28721216; PMCID: PMC5510393.
Copy Download .nbib Format: NLM
Share it on

Endocrinol Diabetes Metab Case Rep. 2017 Jul 07;2017. doi: 10.1530/EDM-17-0055. eCollection 2017.

Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis.

Endocrinology, diabetes & metabolism case reports

B Cangiano, C Cacciatore, L Persani, M Bonomi

Affiliations

  1. Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, MilanItaly.
  2. Department of Clinical Sciences and Community Health, University of Milan, MilanItaly.

PMID: 28721216 PMCID: PMC5510393 DOI: 10.1530/EDM-17-0055

Abstract

We describe a case of severe erythrocytosis caused by testosterone replacement therapy in a 66-year-old man affected with hypogonadotropic hypogonadism (HH) determining osteoporosis, resolved by switching to restoration therapy with clomiphene citrate. The patient complained fatigue, loss of libido and defective erections and a spontaneous vertebral fracture despite bisphosphonate therapy and vitamin D supplementation. The examinations proved isolated HH and he was therefore treated with testosterone gel with regression of specific manifestations but elevated hemoglobin and hematocrit values. Therefore, it was decided to switch to a restoration therapy with clomiphene citrate 25 mg/die, which resulted in the resolution of symptoms without evident side effects. In a couple of months, the patient showed normalization of testosterone levels and increment of testicular volume. Since secondary hypogonadism is the consequence of an insufficient stimulation of the gonads by hypothalamic-pituitary axis, therapeutic approaches aimed to restore endogenous testosterone production should be considered in alternative to testosterone replacement, particularly if side effects intervene. Among these strategies, clomiphene citrate seems to have a high efficacy and safety profile also in the elderly with isolated HH and no evident pituitary lesion.

LEARNING POINTS: Hypogonadism should always be assessed in patients with severe loss in BMD and undergo appropriate medical treatment.In hypogonadotropic hypogonadism, more approaches are available other than testosterone replacement therapy alone.In patients with severe late-onset central hypogonadism presenting with erythrocytosis even at low doses of replacement therapy, restoration therapy with clomiphene could prove to be an effective solution, particularly in patients with a reversible disruption of GNRH/gonadotropin functions.Clomiphene citrate increases gonadotropin levels and testicular volume and should therefore be considered in hypogonadal men who wish to remain fertile.

References

  1. J Clin Endocrinol Metab. 2010 Apr;95(4):1810-8 - PubMed
  2. Asian J Androl. 2015 Mar-Apr;17(2):201-5 - PubMed
  3. Expert Opin Emerg Drugs. 2012 Jun;17(2):239-59 - PubMed
  4. J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):725-35 - PubMed
  5. Clin Interv Aging. 2007;2(4):561-6 - PubMed
  6. BJU Int. 2012 Nov;110(10):1524-8 - PubMed
  7. N Engl J Med. 2004 Jan 29;350(5):482-92 - PubMed
  8. Fertil Steril. 2014 Jan;101(1):64-9 - PubMed
  9. BJU Int. 2016 Dec;118(6):994-1000 - PubMed
  10. Minerva Endocrinol. 2016 Jun;41(2):223-39 - PubMed
  11. J Clin Endocrinol Metab. 1987 Dec;65(6):1118-26 - PubMed

Publication Types